Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-α as second-line treatment of advanced transitional cell cancer of the urothelial tract-Reference-Cited by-同舟云学术

Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-α as second-line treatment of advanced transitional cell cancer of the urothelial tract

Published:2000-11 Issue:11 Volume:11 Page:1391-1394
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

De Mulder P.H.M.,Theodore C.,Sella A.,Koriakine O.,Sternberg C.N.,Collette L.,de Balincourt C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/11/11/1391/19477917/11-11-1391.pdf

Reference20 articles.

1. Chemotherapy of urothelial tract cancer. Memorial Sloan-Kettering Cancer Center experience;Yagoda,1988

2. The chemotherapy of advanced bladder cancer;Newling;Cancer Chemother Pharmacol,1987

3. Gemcitabine in bladder cancer (Review);Sternberg;Semin Oncol,2000

4. Pacltaxel and carboplatin in bladder cancer;Vaughn;Recent developments. Eur J Cancer,2000

5. A randomized trial of cisplatin versus cisplatin plus metotrexate in advanced cancer of the urothelial tract;Hillcoat;J Clin Oncol,1989

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis;OncoTargets and Therapy;2016-03

2. Second-Line Therapies in Metastatic Urothelial Carcinoma;Hematology/Oncology Clinics of North America;2015-04

3. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: A phase II study;Asia-Pacific Journal of Clinical Oncology;2012-08-09

4. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma;Anti-Cancer Drugs;2011-01

5. Vinflunine in the treatment of advanced bladder cancer;Expert Review of Anticancer Therapy;2011-01